GTR Home > Tests > Tempus xT assay

Overview

Test name

Help

Tempus xT assay (xT assay)

Purpose of the test

Help

This is a clinical test intended for Help: Therapeutic management

Condition

Help

2 conditions tested. Click Indication tab for more information.

Methodology

Help
Molecular Genetics
IMicrosatellite instability testing (MSI)
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina HiSeq 4000 System
RRNA analysis
Whole transcriptome RNA sequencing
CSequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina HiSeq 4000 System

Summary of what is tested

593 genes and variants, 1 analytes. Click Methodology tab for more information.

Genes

Analytes

  • whole RNA transcriptome

Clinical validity

Help

Not provided

Clinical utility

Help

Guidance for management

Citations
  • Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. - PubMed ID: 25415047
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Personalized genomic analyses for cancer mutation discovery and interpretation. - PubMed ID: 25877891
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. - PubMed ID: 26304871
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. - PubMed ID: 26378224
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. - PubMed ID: 26992220
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. - PubMed ID: 27197177
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. - PubMed ID: 27273579
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268

Guidance for management

Citations
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268
  • Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. - PubMed ID: 27782854

Guidance for management

Citations
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268
  • Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. - PubMed ID: 28835386

Guidance for management

Citations
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268
  • Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. - PubMed ID: 28873162

Guidance for management

Citations
  • Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. - PubMed ID: 27525268
  • MOLECULAR PROFILING FOR CLINICAL DECISION MAKING IN ADVANCED CANCER: A CLINICAL APPRAISAL (Capdevila J. et al. Journal of Cancer Research and Treatment, 2017)

Testing strategy

Help

The xT assay is an NGS-based cancer genome profiling test that interrogates 595 cancer-related genes in tumor tissue with a matched normal sample as a reference, as well as tumor whole RNA transcriptome for gene rearrangement detection. The assay interrogates SNVs, CNVs, indels, rearrangements/fusions (DNA and RNA), TMB and MSI. The Tempus xT assay uses saliva and blood for germline DNA, and FFPE, bone marrow, and peripheral whole blood for tumor DNA and RNA. A patient can consent to or opt out of receiving genetic cancer predisposition results by completing the Patient Informed Consent form. The Tempus xT gene panel has been designed to specifically target genes known in the literature to be linked with response or resistance to targeted therapies, resistance to standard of care, or toxicities associated with treatment. Furthermore, the Tempus xT assay allows for clinical trial routing based on the most recent literature and clinical trial availability.

How to order

Help

To order the Tempus xT test: 1. Retrieve a Tempus blood, bone marrow or saliva collection kit. All required forms are contained in the box. 2. Complete the Consent Form with the patient. 3. Complete the Requisition Form. Physician and Patient signatures are both required. 4. Complete the Financial Assistance Form with the patient. 5. Fax the Requisition Form, Financial Assistance Form, and accompanying documents to Tempus at 708.575.1789. 6. Once Tempus receives the fax, Tempus will request the tumor specimen (FFPE or bone marrow) from pathology. 7. Retrieve a normal sample of blood or saliva from the patient and ship it using the enclosed FedEx label. Include faxed documents in the package.
Order URL Help: https://www.tempus.com/providers.html

Test services

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Next generation DNA sequencing of 595 genes
  • Whole Transcriptome RNA sequencing

Clinical resources

Practice guidelines

  • Nguyen et al., 2011
    Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center